Dr. Daud on the Combinations of Immunotherapy for Melanoma

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

LAG-3 is being looked at in combination with PD-1, which has shown response in patients who had progressed previously on a PD-1 inhibitor, explains Daud.

Additionally, there are some interesting 4-1BB antibodies that appear to be have some activity when combined. More biomarker research is needed to determine which combination will benefit patients, states Daud.